oxybutynin and Blood Loss, Surgical

oxybutynin has been researched along with Blood Loss, Surgical in 1 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Blood Loss, Surgical: Loss of blood during a surgical procedure.

Research

Studies (1)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Incidence of Adverse Events

(NCT00658723)
Timeframe: 30 days (+14 days)

Incidence of Adverse Events Potentially Related to Transfusion Exposure

The types of events that were potentially related to transfusion exposure could have include hypocalcemia. (NCT00658723)
Timeframe: Intra-operative up to 1 month (+14 days)

Incidence of Adverse Events That Are Potentially Related to Bleeding

The types of events that were potentially related to bleeding included operative hemorrhage and re-bleeding of the target bleeding site (TBS). (NCT00658723)
Timeframe: Intra-operative up to 1 month (+14 days)

Incidence of Adverse Events That Are Potentially Related to Thrombotic Events

The types of events that were potentially related to thrombotic events included deep vein thrombosis and pulmonary embolism (NCT00658723)
Timeframe: Intra-operative up to 1 month (+14 days)

Incidence of Treatment Failures

If hemostasis was not achieved within 4 minutes or if bleeding required additional intervention during the 6 minute observation period, the treatment was considered to be a failure. (NCT00658723)
Timeframe: Intra-operative

Proportion of Subjects Achieving Hemostatic Success

Proportion of success in achieving hemostasis at 4 minutes after randomization with no re-bleeding requiring treatment during a subsequent 6-minute observation period. (NCT00658723)
Timeframe: Intra-operative

Proportion of Subjects Achieving Hemostatic Success

The proportion of subjects achieving hemostatic success at 10 minutes following randomization (NCT00658723)
Timeframe: 10 minutes

Incidence of Re-treatment

"The outcome measure assess if re-treatment was done after release of manual compression at 4-minutes for subjects not achieving hemostatic success or if re-treatment was done during the 6-minute observation period.~In the SURGICEL group, 18 subjects had initial hemostatic success at 4 minutes, but 2 of the 18 subjects were re-treated for re-bleeding. In the SURGICEL group, 12 subjects were not hemostatic at 4-minutes and had a re-treatment." (NCT00658723)
Timeframe: Intra-operative

Absolute Time to Hemostasis

The absolute time to achieve hemostasis at or after 4 minutes from randomization. (NCT01993888)
Timeframe: Intraoperative, an average of 4.2 minutes following randomization

Hemostasis at the Target Bleeding Site (TBS) at 10-minutes Following Randomization

Proportion of subjects achieving hemostatic success at 10 minutes following randomization and no further bleeding requiring treatment prior to initiation of wound closure. (NCT01993888)
Timeframe: Intraoperative, 10 minutes following randomization

Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization

Proportion of subjects achieving hemostasis at the TBS at 4-minutes following randomization and with no re-bleeding requiring treatment at the TBS any time prior to initiation of wound closure. Hemostasis is defined as no detectable bleeding at the TBS. (NCT01993888)
Timeframe: Intraoperative, 4 minutes following randomization

Incidence of Adverse Events That Were Potentially Related to Thrombotic Events

Number of participants with adverse events that were potentially related to thrombic events (NCT01993888)
Timeframe: Up to 60-days following surgery

Incidence of Adverse Events (AEs)

(NCT01993888)
Timeframe: Up to 60-days following surgery

Incidence of Re-bleeding Events From the TBS During the Study Follow-up

(NCT01993888)
Timeframe: Up to 60-days following surgery

Reviews

1 review available for oxybutynin and Blood Loss, Surgical